A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components

Hanne M. Kinnunen, Vikas Sharma, Luis Rodrigo Contreras-Rojas, Yafei Yu, Chlöe Alleman, Alavattam Sreedhara, Stefan Fischer, Leslie Khawli, Stefan T. Yohe, Daniela Bumbaca, Thomas W. Patapoff, Ann L. Daugherty, Randall J. Mrsny

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Subcutaneous (SC) injection is becoming a more common route for the administration of biopharmaceuticals. Currently, there is no reliable in vitro method that can be used to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection. Nor is there an animal model that can predict in vivo outcomes such as bioavailability in humans. We address this unmet need by the development of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator). The system models environmental changes that a biopharmaceutical could experience as it transitions from conditions of a drug product formulation to the homeostatic state of the hypodermis following SC injection. Scissor uses a dialysis-based injection chamber, which can incorporate various concentrations and combinations of acellular extracellular matrix (ECM) components that may affect the release of a biopharmaceutical from the SC injection site. This chamber is immersed in a container of a bicarbonate-based physiological buffer that mimics the SC injection site and the infinite sink of the body. Such an arrangement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can be used to characterize physicochemical changes of the drug and its interactions with ECM components. Movement of a biopharmaceutical from the injection chamber to the infinite sink compartment simulates the drug migration from the injection site and uptake by the blood and/or lymph capillaries. Here, we present an initial evaluation of the Scissor system using the ECM element hyaluronic acid and test formulations of insulin and four different monoclonal antibodies. Our findings suggest that Scissor can provide a tractable method to examine the potential fate of a biopharmaceutical formulation after its SC injection in humans and that this approach may provide a reliable and representative alternative to animal testing for the initial screening of SC formulations.

LanguageEnglish
Pages94-102
Number of pages9
JournalJournal of Controlled Release
Volume214
Early online date22 Jul 2015
DOIs
StatusPublished - 28 Sep 2015

Fingerprint

Subcutaneous Injections
Extracellular Matrix
Injections
Animal Testing Alternatives
In Vitro Techniques
Drug Compounding
Subcutaneous Tissue
Lymph
Hyaluronic Acid
Bicarbonates
Drug Interactions
Biological Availability
Dialysis
Buffers
Animal Models
Monoclonal Antibodies
Insulin

Keywords

  • Biopharmaceuticals
  • Formulation design
  • In vitro model
  • Subcutaneous injection

Cite this

A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. / Kinnunen, Hanne M.; Sharma, Vikas; Contreras-Rojas, Luis Rodrigo; Yu, Yafei; Alleman, Chlöe; Sreedhara, Alavattam; Fischer, Stefan; Khawli, Leslie; Yohe, Stefan T.; Bumbaca, Daniela; Patapoff, Thomas W.; Daugherty, Ann L.; Mrsny, Randall J.

In: Journal of Controlled Release, Vol. 214, 28.09.2015, p. 94-102.

Research output: Contribution to journalArticle

Kinnunen, HM, Sharma, V, Contreras-Rojas, LR, Yu, Y, Alleman, C, Sreedhara, A, Fischer, S, Khawli, L, Yohe, ST, Bumbaca, D, Patapoff, TW, Daugherty, AL & Mrsny, RJ 2015, 'A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components', Journal of Controlled Release, vol. 214, pp. 94-102. https://doi.org/10.1016/j.jconrel.2015.07.016
Kinnunen, Hanne M. ; Sharma, Vikas ; Contreras-Rojas, Luis Rodrigo ; Yu, Yafei ; Alleman, Chlöe ; Sreedhara, Alavattam ; Fischer, Stefan ; Khawli, Leslie ; Yohe, Stefan T. ; Bumbaca, Daniela ; Patapoff, Thomas W. ; Daugherty, Ann L. ; Mrsny, Randall J. / A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. In: Journal of Controlled Release. 2015 ; Vol. 214. pp. 94-102.
@article{1b6d4e7ec2f04bcf9b61d4d062426fde,
title = "A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components",
abstract = "Subcutaneous (SC) injection is becoming a more common route for the administration of biopharmaceuticals. Currently, there is no reliable in vitro method that can be used to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection. Nor is there an animal model that can predict in vivo outcomes such as bioavailability in humans. We address this unmet need by the development of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator). The system models environmental changes that a biopharmaceutical could experience as it transitions from conditions of a drug product formulation to the homeostatic state of the hypodermis following SC injection. Scissor uses a dialysis-based injection chamber, which can incorporate various concentrations and combinations of acellular extracellular matrix (ECM) components that may affect the release of a biopharmaceutical from the SC injection site. This chamber is immersed in a container of a bicarbonate-based physiological buffer that mimics the SC injection site and the infinite sink of the body. Such an arrangement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can be used to characterize physicochemical changes of the drug and its interactions with ECM components. Movement of a biopharmaceutical from the injection chamber to the infinite sink compartment simulates the drug migration from the injection site and uptake by the blood and/or lymph capillaries. Here, we present an initial evaluation of the Scissor system using the ECM element hyaluronic acid and test formulations of insulin and four different monoclonal antibodies. Our findings suggest that Scissor can provide a tractable method to examine the potential fate of a biopharmaceutical formulation after its SC injection in humans and that this approach may provide a reliable and representative alternative to animal testing for the initial screening of SC formulations.",
keywords = "Biopharmaceuticals, Formulation design, In vitro model, Subcutaneous injection",
author = "Kinnunen, {Hanne M.} and Vikas Sharma and Contreras-Rojas, {Luis Rodrigo} and Yafei Yu and Chl{\"o}e Alleman and Alavattam Sreedhara and Stefan Fischer and Leslie Khawli and Yohe, {Stefan T.} and Daniela Bumbaca and Patapoff, {Thomas W.} and Daugherty, {Ann L.} and Mrsny, {Randall J.}",
year = "2015",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2015.07.016",
language = "English",
volume = "214",
pages = "94--102",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components

AU - Kinnunen, Hanne M.

AU - Sharma, Vikas

AU - Contreras-Rojas, Luis Rodrigo

AU - Yu, Yafei

AU - Alleman, Chlöe

AU - Sreedhara, Alavattam

AU - Fischer, Stefan

AU - Khawli, Leslie

AU - Yohe, Stefan T.

AU - Bumbaca, Daniela

AU - Patapoff, Thomas W.

AU - Daugherty, Ann L.

AU - Mrsny, Randall J.

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Subcutaneous (SC) injection is becoming a more common route for the administration of biopharmaceuticals. Currently, there is no reliable in vitro method that can be used to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection. Nor is there an animal model that can predict in vivo outcomes such as bioavailability in humans. We address this unmet need by the development of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator). The system models environmental changes that a biopharmaceutical could experience as it transitions from conditions of a drug product formulation to the homeostatic state of the hypodermis following SC injection. Scissor uses a dialysis-based injection chamber, which can incorporate various concentrations and combinations of acellular extracellular matrix (ECM) components that may affect the release of a biopharmaceutical from the SC injection site. This chamber is immersed in a container of a bicarbonate-based physiological buffer that mimics the SC injection site and the infinite sink of the body. Such an arrangement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can be used to characterize physicochemical changes of the drug and its interactions with ECM components. Movement of a biopharmaceutical from the injection chamber to the infinite sink compartment simulates the drug migration from the injection site and uptake by the blood and/or lymph capillaries. Here, we present an initial evaluation of the Scissor system using the ECM element hyaluronic acid and test formulations of insulin and four different monoclonal antibodies. Our findings suggest that Scissor can provide a tractable method to examine the potential fate of a biopharmaceutical formulation after its SC injection in humans and that this approach may provide a reliable and representative alternative to animal testing for the initial screening of SC formulations.

AB - Subcutaneous (SC) injection is becoming a more common route for the administration of biopharmaceuticals. Currently, there is no reliable in vitro method that can be used to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection. Nor is there an animal model that can predict in vivo outcomes such as bioavailability in humans. We address this unmet need by the development of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator). The system models environmental changes that a biopharmaceutical could experience as it transitions from conditions of a drug product formulation to the homeostatic state of the hypodermis following SC injection. Scissor uses a dialysis-based injection chamber, which can incorporate various concentrations and combinations of acellular extracellular matrix (ECM) components that may affect the release of a biopharmaceutical from the SC injection site. This chamber is immersed in a container of a bicarbonate-based physiological buffer that mimics the SC injection site and the infinite sink of the body. Such an arrangement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can be used to characterize physicochemical changes of the drug and its interactions with ECM components. Movement of a biopharmaceutical from the injection chamber to the infinite sink compartment simulates the drug migration from the injection site and uptake by the blood and/or lymph capillaries. Here, we present an initial evaluation of the Scissor system using the ECM element hyaluronic acid and test formulations of insulin and four different monoclonal antibodies. Our findings suggest that Scissor can provide a tractable method to examine the potential fate of a biopharmaceutical formulation after its SC injection in humans and that this approach may provide a reliable and representative alternative to animal testing for the initial screening of SC formulations.

KW - Biopharmaceuticals

KW - Formulation design

KW - In vitro model

KW - Subcutaneous injection

U2 - 10.1016/j.jconrel.2015.07.016

DO - 10.1016/j.jconrel.2015.07.016

M3 - Article

VL - 214

SP - 94

EP - 102

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -